All In Biotech

Drug Trial Radar · NCT01256424

Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia

A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)

Last checked: Nov 20, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Apr 2011

Primary completion

Sep 2012

Study completion Dec 2012

Sponsor

Lead sponsor
PhotocureIndustry
Sponsor type
Industry
First posted
Dec 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An effective and safe medical therapy would be most welcome to reduce the need for surgical interventions and related adverse events and psychological impact on patients with cervical cancer precursors. In this clinical trial, the investigators propose to evaluate the efficacy and safety of photodynamic therapy (PDT) using hexaminolevulinate (HAL) for mild to moderate-grade CIN (grade 1-2).

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

  • HAL 5% with illuminationDrug

    Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation

  • HAL 1% with illuminationDrug

    Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation

  • HAL 0.2% with illuminationDrug

    Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation

  • Placebo ointment without illuminationDrug

    Treatment with a singe dose of 2g placebo ointment, no photoactivation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.Time frame: 3 months after last treatment

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University Hospital Hannover

    Hanover, Germany

  • Haukeland University Hospital

    Bergen, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.